Metastatic Ovarian Cancer - Pipeline Review, H2 2016

  • ID: 3946454
  • Drug Pipelines
  • 105 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Cellceutix Corporation
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Immune Design Corp.
  • MolMed S.p.A.
  • Natco Pharma Limited
  • MORE
Metastatic Ovarian Cancer - Pipeline Review, H2 2016

Summary

Our latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Ovarian Cancer - Pipeline Review, H2 2016, provides an overview of the Metastatic Ovarian Cancer (Oncology) pipeline landscape.

Metastatic ovarian cancer is a type of cancer that originates in the ovaries, but then spreads to other areas of the body, such as the diaphragm, intestine, mentum (a fatty layer that covers and pads abdominal organs), liver or lungs. Symptoms include fatigue, getting full quickly, abdominal swelling, leg swelling, changes in bowel habits, and changes in bladder habits, abdominal pain, and shortness of breath. Metastatic ovarian cancer is often treated with a combination of therapies that can include surgery, chemotherapy and radiation therapy.

Report Highlights

Our Pharmaceutical and Healthcare latest pipeline guide Metastatic Ovarian Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Metastatic Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Metastatic Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Metastatic Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 7, 9 and 2 respectively for Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively for Metastatic Ovarian Cancer.

Metastatic Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Metastatic Ovarian Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Metastatic Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Metastatic Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Metastatic Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Ovarian Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Metastatic Ovarian Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Metastatic Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Cellceutix Corporation
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Immune Design Corp.
  • MolMed S.p.A.
  • Natco Pharma Limited
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Metastatic Ovarian Cancer Overview

Therapeutics Development

Pipeline Products for Metastatic Ovarian Cancer - Overview

Pipeline Products for Metastatic Ovarian Cancer - Comparative Analysis

Metastatic Ovarian Cancer - Therapeutics under Development by Companies

Metastatic Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes

Metastatic Ovarian Cancer - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Metastatic Ovarian Cancer - Products under Development by Companies

Metastatic Ovarian Cancer - Products under Investigation by Universities/Institutes

Metastatic Ovarian Cancer - Companies Involved in Therapeutics Development

Adgero Biopharmaceuticals Inc

Cellceutix Corporation

Eisai Co., Ltd.

F. Hoffmann-La Roche Ltd.

Immune Design Corp.

Millennium Pharmaceuticals Inc

MolMed S.p.A.

Natco Pharma Limited

Northwest Biotherapeutics, Inc.

Pfizer Inc.

Richter Gedeon Nyrt.

Sumitomo Dainippon Pharma Co., Ltd.

VG Life Sciences, Inc.

Metastatic Ovarian Cancer - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

Antisense RNAi Oligonucleotide to Replace MicroRNA-138 for Metastatic Ovarian Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bevacizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMB-305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

crizotinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DCVax-Direct - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DCVax-L - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-7449 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emactuzumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gedatolisib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hydroxychloroquine + sorafenib tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kevetrin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LV-305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NGR-hTNF - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NRCAN-019 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

orteronel - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OS-2966 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REM-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SM-276001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Metastatic Ovarian Cancer - Dormant Projects

Metastatic Ovarian Cancer - Discontinued Products

Metastatic Ovarian Cancer - Product Development Milestones

Featured News & Press Releases

Jun 22, 2015: VG Life Sciences Granted Combination Cancer Drug Patent

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Metastatic Ovarian Cancer, H2 2016

Number of Products under Development for Metastatic Ovarian Cancer - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Metastatic Ovarian Cancer - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016

Metastatic Ovarian Cancer - Pipeline by Cellceutix Corporation, H2 2016

Metastatic Ovarian Cancer - Pipeline by Eisai Co., Ltd., H2 2016

Metastatic Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016

Metastatic Ovarian Cancer - Pipeline by Immune Design Corp., H2 2016

Metastatic Ovarian Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016

Metastatic Ovarian Cancer - Pipeline by MolMed S.p.A., H2 2016

Metastatic Ovarian Cancer - Pipeline by Natco Pharma Limited, H2 2016

Metastatic Ovarian Cancer - Pipeline by Northwest Biotherapeutics, Inc., H2 2016

Metastatic Ovarian Cancer - Pipeline by Pfizer Inc., H2 2016

Metastatic Ovarian Cancer - Pipeline by Richter Gedeon Nyrt., H2 2016

Metastatic Ovarian Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016

Metastatic Ovarian Cancer - Pipeline by VG Life Sciences, Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Metastatic Ovarian Cancer - Dormant Projects, H2 2016

Metastatic Ovarian Cancer - Discontinued Products, H2 2016

List of Figures

Number of Products under Development for Metastatic Ovarian Cancer, H2 2016

Number of Products under Development for Metastatic Ovarian Cancer - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Top 10 Molecule Types, H2 2016

Number of Products by Stage and Top 10 Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Adgero Biopharmaceuticals Inc
Cellceutix Corporation
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
Immune Design Corp.
Millennium Pharmaceuticals Inc
MolMed S.p.A.
Natco Pharma Limited
Northwest Biotherapeutics, Inc.
Pfizer Inc.
Richter Gedeon Nyrt.
Sumitomo Dainippon Pharma Co., Ltd.
VG Life Sciences, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll